However, patients with SMA present with varying degrees of severity depending on the number of SMN2 copies, a finding that has also been replicated in SMA mouse models [7,11,12], indicating that SMN2 could serve as the SMA modifier and is therefore a natural target for SMA therapy [12-16]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.